Ben Samelson-Jones: Do Gene Variants Drive PK Differences in FIX-Fusion and N9-GP Therapies?
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JTH, adding:
“As hemophilia treatments become more sophisticated, understanding the role of the dysfunctional F9 variant becomes more important.”
Title: Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates
Authors: Davide Matino, Zainab Al-Housni, Benjamin Samelson-Jones, Pierre Chelle, Giancarlo Castaman, Jerome Teitel, Shannon Jackson, David Lillicrap, Arun Keepanasseril, Anthony Chan, Kyumin Lee, Andrea Edginton, Alfonso Iorio
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 12, 2026, 16:35Mohamed Hesham Gamal: Intravenous Thrombolysis Shows Strong Safety Profile in Stroke Mimics
-
Nov 12, 2026, 14:35Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity
-
Nov 12, 2026, 14:25Kim Phelan: Celebrating Dr. Marilyn Manco-Johnson as a Recipient of the 2026 Eternal Spirit Award
-
Nov 12, 2026, 14:20Shailesh Kucha: Ensuring Transfusion Safety Through Biochemical Assessment of Stored Red Cells
-
Nov 12, 2026, 14:20Akshat Jain: Wonderful Time Presenting at the ATHN 2026
-
Nov 12, 2026, 14:08Elisa Gabinaud: The Evolving Science of Megakaryocyte Development
-
Nov 12, 2026, 13:57Seyed Mohammad Sadegh Pezeshki: When Microcytosis Reveals a Complex Hemoglobinopathy
-
Nov 12, 2026, 13:45Danny Hsu: THANZ Highlights Antiphospholipid Syndrome in Upcoming Educational Webinar
-
Nov 12, 2026, 13:04Wuhan Thrombosis Congress 2026 – Bringing Global Experts Together – ISTH